[Effect of the hexapeptide dalargin on ornithine decarboxylase activity in the duodenal mucosa of rats in experimental duodenal ulcer].
The effect of an opioid antiulcerogenic hexapeptide dalargin on ornithine decarboxylase activity of duodenal mucosa has been studied in rats with experimental duodenal ulcers induced by cysteamine. The intraperitoneal injection of 12.5 micrograms/kg of dalargin inhibited ulcerogenesis and activated the enzyme. The effect of the peptide was antagonized by an opiate antagonist naloxone. 5000 micrograms/kg of dalargin failed to inhibit the ulcer formation or to activate ornithine decarboxylase. Since ornithine decarboxylase activation is a marker of intensified cell proliferation and tissue regeneration, our results suggest that the antiulcerogenic effect of dalargin is due to the enhancement of duodenal mucosa regeneration.
D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D003543:Cysteamine; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology; D004386:Duodenum / Q000187:drug effects* / Q000201:enzymology; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives*; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D009955:Ornithine Decarboxylase / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains
D000897:Anti-Ulcer Agents; D004743:Enkephalin, Leucine; D003543:Cysteamine; D016308:Enkephalin, Leucine-2-Alanine; D009955:Ornithine Decarboxylase; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
Vliianie geksapeptida dalargina na aktivnost' ornitindekarboksilazy v slizistoĭ obolochke dvenadtsatiperstnoĭ kishki krys s éksperimental'noĭ duodenal'noĭ iazvoĭ.